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Disease and Mortality, and Possible Adverse Effects
Trine Holm Johannsen, MD, PHD,*† Ruth Frikke-Schmidt, MD, DMSC,*† Jesper Schou, MSC,*†
Børge G. Nordestgaard, MD, DMSC,†‡§ Anne Tybjærg-Hansen, MD, DMSC*†§
Copenhagen, Denmark
Objectives This study tested whether genetic variation in the CETP gene is consistent with a protective effect of cholesteryl
ester transfer protein (CETP) inhibition on risk of ischemic events and on total mortality, without the adverse ef-
fects reported for torcetrapib.
Background Torcetrapib, an inhibitor of CETP, increased risk of death and ischemic cardiovascular disease of those random-
ized to the drug, despite improving the lipid profile.
Methods The Copenhagen City Heart Study is a prospective cohort study of 10,261 individuals, aged 20 to 93 years, who
were followed for up to 34 years (1976 to 2010). Of these, 2,087 developed ischemic heart disease, 1,064 de-
veloped ischemic cerebrovascular disease, and 3,807 died during follow-up. We selected 2 common genetic
variants in CETP previously associated with reductions in CETP activity, thus mimicking the effect of pharmaco-
logical CETP inhibition.
Results In individuals carrying 4 versus 0 high-density lipoprotein cholesterol–increasing alleles, there was an increase in
levels of high-density lipoprotein cholesterol of up to 14% (0.2 mmol/l), and concomitant decreases in triglycer-
ides, low-density lipoprotein cholesterol, and non–high-density lipoprotein cholesterol of, respectively, 6% (0.1
mmol/l), 3% (0.1 mmol/l), and 4% (0.2 mmol/l) (p for trend 0.004 to 0.001). Corresponding hazard ratios
were 0.76 (95% confidence interval [CI]: 0.68 to 0.85) for any ischemic vascular event, 0.74 (95% CI: 0.65 to
0.85) for ischemic heart disease, 0.65 (95% CI: 0.54 to 0.79) for myocardial infarction, 0.77 (95% CI: 0.65 to
0.93) for ischemic cerebrovascular disease, 0.71 (95% CI: 0.58 to 0.88) for ischemic stroke, and 0.88 (95% CI:
0.80 to 0.97) for total mortality. CETP genotypes did not associate with variation in markers of possible side ef-
fects previously reported for torcetrapib.
Conclusions Genetic CETP inhibition associates with reductions in risk of ischemic heart disease, myocardial infarction, isch-
emic cerebrovascular disease, and ischemic stroke, with a corresponding antiatherogenic lipid profile, and with
increased longevity, without adverse effects. (J Am Coll Cardiol 2012;60:2041–8) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.045Risk factors for atherosclerosis include elevated levels of
low-density lipoprotein (LDL) and triglyceride-rich rem-
nant lipoproteins (i.e., intermediate-density lipoproteins,
very low-density lipoproteins, and chylomicron remnants),
and decreased levels of high-density lipoproteins (HDL)
(1–3). Cholesteryl ester transfer protein (CETP) facilitates
exchange of cholesteryl esters for triglycerides between
HDL and triglyceride-rich remnant lipoproteins (4), and
although this exchange clearly may affect several atherogenic
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HDL cholesterol alone.
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Because of the inverse relationship between HDL choles-
terol and risk of IHD in observational studies, development of
drugs to raise HDL cholesterol has been proposed, including
Physician Johan Boserup and Lise Boserup’s Fund; Ingeborg and Leo Dannin’s Grant;
Henry Hansen’s and Wife’s Grant; William Nielsen’s Fund; and a grant from the Odd
Fellow Order. Dr. Nordestgaard has received lecture and/or consultancy honoraria from
AstraZeneca, Merck & Co., Inc., Pfizer Inc., Karo Bio, Omthera Pharmaceuticals, Inc.,
Abbott, Sanofi-Aventis, and Regeneron. All other authors have reported that they have
no relationships relevant to the contents of this paper to disclose.Manuscript received March 20, 2012; revised manuscript received June 18, 2012,
accepted July 3, 2012.
c
a
M
I
e
w
q
i
s
l
p
f
t
t
t
c
C
i
w
t
l
m
p
w
p
i
p
a
l
i
c
m
i
i
t
M
P
i
t
r
R
a
p
d
w
d
O
s
D
D
o
G
p
r
t
T
b
O
S
C
T
G
C
p
s
r
2042 Johannsen et al. JACC Vol. 60, No. 20, 2012
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however, despite a 72% increase in
HDL cholesterol, patients treated
with the CETP-inhibitor torce-
trapib in the ILLUMINATE (In-
vestigation of Lipid Level Manage-
ment to Understand Its Impact in
Atherosclerotic Events) trial had a
paradoxical increase in mortality and
an increase in major cardiovascular
events (5). The exact reason for the
failure of torcetrapib is uncertain
(6,7), but has led to a re-evaluation
of CETP inhibition as a mechanism
to raise HDL cholesterol and HDL
cholesterol raising itself as an anti-
atherogenic strategy (8). Moreover,
the recent premature terminations of
the dal-OUTCOMES trial (9), due
to lack of clinically meaningful effi-
acy on cardiovascular events of the CETP inhibitor dalcetrapib,
nd of the AIM-HIGH (Atherothrombosis Intervention in
etabolic Syndrome With Low HDL/High Triglycerides:
mpact on Global Health Outcomes) study, due to lack of
ffect of niacin added to simvastatin in high-risk individuals
ith low HDL cholesterol and high triglycerides, further
uestions the value of CETP inhibition and HDL cholesterol–
ncreasing therapy per se (10–12).
However, more recent studies designed to evaluate the
ide effects and overall safety profiles and the effects on lipid
evels of 3 newer CETP inhibitors showed favorable lipid
rofiles and acceptable side effect profiles (13–15). There-
ore, the most plausible explanations for the failure of
orcetrapib are that pharmacological CETP inhibition ei-
her: 1) has off-target effects that might be specific for
orcetrapib; or 2) causes a disproportionate increase in HDL
holesterol, which may be harmful.
We examined the hypothesis that genetic variation in
ETP is consistent with a protective effect of CETP
nhibition on risk of ischemic events and on total mortality,
ithout the adverse effects previously reported for torce-
rapib. To maximize power, we used genotype scores for
ipids, lipoproteins, apolipoproteins, disease endpoints, and
ortality for 2 very common single nucleotide polymor-
hisms (SNP) that were previously reported to associate
ith reductions in CETP activity (16–23), thus mimicking
harmacological CETP inhibition. Using individual partic-
pant data, we determined the association of the CETP
olymorphisms 629 CA and IVS1279 GA(Taq1B)
s individual and combined genotypes, with: 1) changes in
ipid, lipoprotein, and apolipoprotein levels; 2) risk of any
schemic event, IHD, myocardial infarction (MI), ischemic
erebrovascular disease (ICVD), ischemic stroke (IS), and
ortality with up to 34 years of follow-up; and 3) changes
Abbreviations
and Acronyms
CETP  cholesteryl ester
transfer protein
CI  confidence interval
HDL  high-density
lipoprotein
HR  hazard ratio
ICVD  ischemic
cerebrovascular disease
IHD  ischemic heart
disease
IS  ischemic stroke
LDL  low-density
lipoprotein
MI  myocardial infarction
SNP  single nucleotide
polymorphismn blood pressure, electrolytes, renal and liver function, and an the electrocardiogram affected by treatment with
orcetrapib.
ethods
articipants. The CCHS (Copenhagen City Heart Study)
s a population-based prospective study initiated from 1976
o 1978 (24–28). Participants aged 20 years or older were
andomly invited from the Danish Central Population
egister and re-examined from 1981 to 1983, 1991 to 1994,
nd 2001 to 2003. We included 10,261 participants in the
resent analysis, of which 2,087 developed IHD, and 1,064
eveloped ICVD; 3,807 died during follow-up. Follow-up
as up to 34 years and was 100% complete. For a detailed
escription of study endpoints and follow-up, please see the
nline Appendix.
All participants were white and of Danish descent. The
tudy was approved by institutional review boards and by
anish ethical committees and conducted according to the
eclaration of Helsinki. Written informed consent was
btained from all participants.
enotyping and biochemical analyses. Genotyping was
erformed for 2 common SNPs in the CETP gene,
s1800775 CA, in the promoter at position 629 relative
o the transcriptional start site, and rs708272 GA, the
aq1B polymorphism, in intervening sequence 1279. For
iochemical analyses and other covariates, please see the
nline Appendix.
tatistical analyses. Stata software (version 10.1, Stata
orp., College Station, Texas) was used for all analyses.
he Mann-Whitney U test or Kruskal-Wallis analysis of
variance was used for continuous variables, and the Pearson
chi-square test was used for categorical variables. For trend
tests, the groups of subjects were classified according to CETP
genotype or genotype combinations, coded as 0, 1, 2, 3, and 4.
From the 2 CETP polymorphisms, we generated 4 genotype
combinations based on the number of HDL-raising alleles
in the individual genotype (Online Table 1): Noncarrier (no
HDL-raising alleles  reference group: 629 CCTaq1B
G, n  2,621; white cell), 1 HDL-raising allele (629
ATaq1B GG or629 CCTaq1B GA, n 537 76
613; red cells), 2 alleles (629 CATaq1B GA or 629
AATaq1B GG or 629 CCTaq1B AA, n  4510 
45  12  4,567; yellow cells), 3 alleles (629 CATaq1B
AA or 629 AATaq1B GA, n  37  471  508; blue
cells), and 4 alleles (629 AATaq1B AA, n 1,952; green
cell). Cuzick nonparametric test for trend was used to test for
differences in lipid, lipoprotein, and apolipoprotein levels be-
tween CETP genotypes and genotype combinations.
Kaplan-Meier curves and tests for trend evaluated the
cumulative incidence of any ischemic event as a function of
age and CETP genotypes, individually and combined. Cox
roportional hazard regression models, using age as time
cale and delayed entry (left truncation), estimated hazard
atios (HRs) for any ischemic event, IHD, MI, ICVD, IS,
nd total mortality as a function of CETP genotypes and
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November 13, 2012:2041–8 CETP and Ischemic Vascular Diseasegenotype combinations. Because age was the time scale, age
was automatically adjusted for. Multifactorial adjustment
was used for sex, body mass index, hypertension, diabetes
mellitus, smoking, lipid-lowering therapy, alcohol con-
sumption, physical inactivity, and for women, post-
menopausal status and hormone replacement therapy.
Results
As previously reported (16–20), CETP 629 CA(rs1800775)
and Taq1B GA(rs708272) were in linkage disequilibrium
(D=  0.97, R2  0.78) (Online Table 1), although in
pproximately 11% of individuals (6% of haplotypes), the
inor alleles were not inherited on the same haplotype. The
inor allele frequency was 0.49 for629 CA and 0.44 for
aq1B GA. Selected clinical characteristics of the partic-
pants in the CCHS with and without events are shown in
nline Table 2.
lasma lipids, lipoproteins, and apolipoproteins. Rela-
ive to CC noncarriers of 629 CA, the AA genotype
as associated with 13% (0.2 mmol/l) higher HDL choles-
erol levels, 6% (0.1 mmol/l) lower triglyceride levels, 3%
0.1 mmol/l) lower LDL cholesterol levels, and 3% (0.2
mol/l) lower non-HDL cholesterol levels (p for trend 0.02
o 0.001) (Fig. 1). Relative to GG noncarriers of Taq1B
A, the AA genotype was associated with similar varia-
ions in lipids and lipoproteins (p for trend 0.001).
However, both SNPs on the wild-type, Taq1B GG or
629 CC, background of the other SNP (corresponding to
ndividuals framed in black in, respectively, row 1 [n 
,709] and column 1 [n  3,203] of Online Table 1), were
lso independently associated with increased levels of HDL
holesterol, with the largest increase of up to 17% in Taq1B
A homozygotes on the 629 CC wild-type background
Figure 1 Plasma Levels of Lipids and Lipoproteins as a Functio
629 C>A and Taq1B G>A Genotypes and Genotype
Values shown are mean  SE, and p values are nonparametric tests for trend. HDp for trend  0.02 and 0.03, respectively) (Online Fig. 1;
genotypes indicated in left column). In addition, Taq1B
genotype on the 629 CC wild-type background was
associated with stepwise reductions in levels of lipopro-
tein(a) of up to 39% in AA homozygotes (p for trend 
0.02) (Online Fig. 1).
Collapsing all genotypes into 5 genotype groups with,
respectively, 0 (reference group), 1, 2, 3, or 4 HDL
cholesterol-raising minor alleles (0 to 4 A alleles) (Online
Table 1) resulted in stepwise increases in HDL cholesterol
of up to 14% (0.2 mmol/l) and concomitant stepwise
decreases of up to 6% (0.1 mmol/l) in triglycerides, 3% (0.1
mmol/l) in LDL cholesterol, and 4% (0.2 mmol/dl) in
non-HDL cholesterol in carriers of 4 A alleles compared
with 0 A alleles (genotype 629 CC and Taq1B GG; p for
trend 0.004 to 0.001) (Fig. 1).
Results for apolipoproteins A-I and B were similar to but
attenuated compared with results for HDL cholesterol and
non-HDL cholesterol, respectively, both overall (compare
Fig. 1 with Online Fig. 2) and on the wild-type background
of the other variant (compare Online Fig. 1 with Online
Fig. 3). In contrast, CETP genotypes did not associate with
apolipoprotein E levels (Online Figs. 2 and 3).
Risk of ischemic vascular disease. In total, 2,743 individ-
uals developed ischemic vascular disease (IHD or ICVD)
during 34 years of follow-up in the CCHS. There was a
stepwise decrease in cumulative incidence of any ischemic
event as a function of CETP genotype with the AA
homozygotes having the lowest incidence for both  SNPs
(Fig. 2, top and middle panel) and with a gradual reduction
in risk as a function of the number of A alleles for the
combined genotypes (Fig. 2, lower panel) (all p for trend
0.001).
holesteryl Ester Transfer Protein
binations in the General Population
igh-density lipoprotein; LDL  low-density lipoprotein.n of C
Com
L  h
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CETP and Ischemic Vascular Disease November 13, 2012:2041–8Compared with the 629 wild-type (CC), the heterozy-
gous (CA) and homozygous (AA) genotypes were associ-
ated with stepwise reductions in risk of ischemic events of
14% (hazard ratio [HR]: 0.86, 95% confidence interval
[CI]: 0.78 to 0.94) and 21% (HR: 0.79, 95% CI: 0.72 to
0.88), respectively (Table 1). Compared with the Taq1B
wild-type (GG), the heterozygous (GA) and homozygous
(AA) genotypes were associated with similar stepwise re-
ductions in risk of 15% (HR: 0.85, 95% CI: 0.78 to 0.93)
and 23% (HR: 0.77, 95% CI: 0.69 to 0.86), respectively. For
Figure 2
Cumulative Incidence of Any Ischemic Event (Ischemic
Heart Disease or Ischemic Cerebrovascular Disease)
as a Function of Age and by Cholesteryl Ester Transfer
Protein 629 C>A and Taq1B G>A Genotypes and
Genotype Combinations in the General Population
Participants with ischemic heart disease and/or ischemic cerebrovascular dis-
ease before entry were excluded. The p values are tests for trend with the
3 genotypes coded 0, 1, and 2.the combined genotypes, there was a gradual reduction inrisk as a function of increasing number of A alleles of up to
24% (HR: 0.76, 95% CI: 0.68 to 0.85) for genotypes with 4
versus 0 A alleles (all p for trend 0.001) (Table 1).
Similar stepwise reductions in risk as a function of
genotype were observed for IHD and ICVD separately and
for the subgroups MI and IS (Fig. 3). For the combined
genotypes, there were stepwise reductions in risks for all
endpoints as a function of increasing number of A alleles of
up to 26% (HR: 0.74, 95% CI: 0.65 to 0.85) for IHD, 35%
(HR: 0.65, 95% CI: 0.54 to 0.79) for MI, 23% (HR: 0.77,
95% CI: 0.65 to 0.93) for ICVD, and 29% (HR: 0.71, 95%
CI: 0.58 to 0.88) for IS, for genotypes with 4 versus 0 A
alleles (p for trend 0.006 to 0.001) (Fig. 3).
Mortality. In total, 3,807 participants died during follow-
up. Compared with the 629 wild-type (CC), the
heterozygous (CA) and homozygous (AA) genotypes were
associated with a stepwise reduction in risk of overall
mortality of 6% (HR: 0.94, 95% CI: 0.87 to 1.02) and 10%
(HR: 0.90, 95% CI: 0.82 to 0.98), respectively (Fig. 4). The
heterozygous (GA) and homozygous (AA) genotypes for
Taq1B were associated with similar reductions in overall
mortality of 3% (HR: 0.97, 95% CI: 0.90 to 1.04) and 11%
(HR: 0.89, 95% CI: 0.82 to 0.98), respectively, compared
with wild type (GG). For the combined genotypes, there
was a stepwise reduction in overall mortality of up to 12%
(HR: 0.88, 95% CI: 0.80 to 0.97) in the group with 4 versus
0 A alleles (all p for trend  0.02) (Fig. 4).
Paraclinical characteristics. CETP genotypes, individually
or combined, were not consistently associated with variation
in vital signs (systolic and diastolic blood pressure, heart
rate), plasma levels of electrolytes (potassium, sodium,
chloride), renal function (creatinine, estimated glomerular
filtration rate), liver function (alanine aminotransferase,
alkaline phosphatase, bilirubin, gamma-glutamyl transpep-
tidase), or other selected measures (duration of the QT
interval corrected for heart rate, and high-sensitivity
C-reactive protein) (Online Tables 3 and 4).
Discussion
The principal findings of this study are that the combination
of 2 common CETP polymorphisms previously shown to be
associated with reduced CETP activity (16–23), not only
predicted stepwise, per allele decreases in risk of IHD and
MI, but also predicted corresponding decreases in risk of
ICVD, IS, and mortality in the general population. In
agreement with the protective effects on all ischemic end-
points and on mortality, the same polymorphisms were
associated with an antiatherogenic lipid profile with step-
wise, per allele increases in levels of HDL cholesterol and
apolipoprotein A-I, and decreased levels of triglycerides,
LDL cholesterol, non-HDL cholesterol, and apolipopro-
tein B. Finally, CETP genotypes did not associate with
variation in systolic and diastolic blood pressure, plasma
levels of electrolytes, renal function tests, liver function tests,
or duration of the QT interval, all markers of possible side
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November 13, 2012:2041–8 CETP and Ischemic Vascular Diseaseeffects previously reported for torcetrapib. These data are
novel and suggest that (genetic) inhibition of CETP reduces
risk of all ischemic vascular events and increases longevity in
a dose-dependent manner, without the side effects previ-
ously reported for torcetrapib.
This is the first study of CETP genotype scores with
concomitant assessment of all ischemic endpoints including
mortality, lipid, lipoprotein, and apolipoprotein levels, in-
cluding lipoprotein(a) and apolipoprotein E, and possible
adverse effects in a prospective study with a long follow-up
in both sexes. Though consistent with the findings in
previous studies on risk of coronary disease or MI
(22,29,30), the present study is more definitive and extends
findings to ICVD and IS, as well as to total mortality.
Another strength is the analysis of 2 different  SNPs,
which, although in partial linkage disequilibrium, allow
calculation of meaningful genotype scores for lipoprotein
and disease endpoints. Furthermore, because we included
individual participant data as opposed to tabular meta-
analyses (22,23), we could avoid some of the biases inherent
to these types of studies. We included both sexes and up to
34 years of follow-up and had 2,087 incident IHD and
1,064 ICVD events, as opposed to a previous prospective
study including approximately 18,000 women followed up
to 15 years and including 198 incident MI events (29). For
the individual genotypes, the observed per A allele increase
in HDL cholesterol and the decrease in triglycerides and
LDL cholesterol, as well as the observed reduction in risk of
IHD and MI in the present study was larger per A allele
than in a recent tabular meta-analysis (22), but very similar
to the lipid and lipoprotein effects and hazard ratios ob-
served for MI in the prospective Women’s Genome Health
Study (29). Finally, due to the extensive phenotyping of
biochemical and other quantities in the present study, we
were able to comprehensively evaluate markers of possible
side effects of moderate CETP inhibition.
We cannot conclude that the reduction in risk per A allele
Risk of Any Ischemic Event During 34 Years of Follow-Up AccordinTable 1 Risk of Any Ischemic Event During 34 Years of Follow-
Participants, n Events, n
Incidenc
Events/1
629 CA CC 2,709 805 12
(rs1800775) CA 5,084 1,308 11
AA 2,468 630 10
Taq1B GA GG 3,203 952 12
(rs708272) GA 5,057 1,290 11
AA 2,001 501 10
629Taq1B Noncarrier 2,621 785 13
1 A allele 613 171 11
2 A alleles 4,567 1,160 11
3 A alleles 508 139 11
4 A alleles 1,952 488 10
Any ischemic event comprises ischemic heart disease and/or ischemic cerebrovascular disease.
therapy (except lipids and lipoproteins).
CI  confidence interval.can be explained by the associated increased HDL choles- aterol levels per se, because we observed corresponding but
lesser reductions in nonfasting triglycerides—a marker of
cholesterol in remnant lipoproteins (24,26,31–33)—LDL
cholesterol, and non-HDL cholesterol, all of which are
atherogenic (34,35). In contrast, our analyses suggest that
individuals with a lifelong increase in HDL cholesterol
together with reductions in nonfasting triglycerides, LDL
cholesterol, and non-HDL cholesterol due to low levels of
CETP activity may be at reduced risk, not only for IHD and
MI as suggested previously by some (22,29,30) but not all
studies (36,37), but in addition for ICVD, and IS and they may
also live longer. That the effect on risk of ischemic cardiovas-
cular events in the present study is not likely explained by levels
of HDL cholesterol per se is supported by recent genome-wide
association studies demonstrating that genetic variants associ-
ated with isolated effects on levels of HDL cholesterol are not
associated with cardiovascular risk (38,39).
Results from the present study suggest that in humans
even moderate reductions in CETP activity may reduce risk
of ischemic vascular events and mortality. Nonetheless,
short-term pharmacological CETP inhibition with torce-
trapib 60 mg daily increased both morbidity and mortality
from cardiovascular events (5). A plausible explanation for
this is that torcetrapib has off-target effects, mainly on blood
pressure, which do not seem to be shared with other
chemically dissimilar CETP inhibitors (13–15). To deter-
mine whether genetic reduction of CETP activity had
similar adverse effects as reported for torcetrapib, we deter-
mined the effect of CETP genotypes, individually and
ombined, on blood pressure, heart rate, electrolytes, renal
nd liver function, QT interval, and high-sensitivity
-reactive protein. We observed no consistent differences as
function of genotypes on any parameters, in complete
ccordance with the findings discussed herein and with a
ecent study suggesting that the hypertensive effect of
orcetrapib is likely an off-target effect (13–15,23).
Another possible explanation for the torcetrapib-induced
ETP Genotype in the General Populationccording to CETP Genotype in the General Population
(95% CI),
Person-Yrs
Hazard Ratio (95% CI)
p Value
TrendAdjusted, age Adjusted, multifactorially
–138) 1.0 1.0
–117) 0.87 (0.80–0.95) 0.86 (0.78–0.94) 0.001
–118) 0.82 (0.74–0.91) 0.79 (0.72–0.88)
–137) 1.0 1.0
–116) 0.87 (0.80–0.95) 0.85 (0.78–0.93) 0.001
116) 0.79 (0.71–0.88) 0.77 (0.69–0.86)
–139) 1.0 1.0
–138) 0.92 (0.78–1.09) 0.93 (0.79–1.10)
–116) 0.86 (0.78–0.94) 0.84 (0.76–0.92) 0.001
–140) 0.92 (0.77–1.10) 0.89 (0.74–1.07)
116) 0.78 (0.70–0.88) 0.76 (0.68–0.85)
ctorial adjustment is adjustment for the factors listed in Online Table 2, including lipid-loweringg to CUp A
e Rate
0,000
9 (120
1 (105
9 (101
9 (121
0 (104
6 (97–
0 (121
9 (102
0 (103
9 (101
6 (97–
Multifadverse effects on cardiovascular endpoints is that torce-
w
w
i
s
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CETP and Ischemic Vascular Disease November 13, 2012:2041–8trapib caused a potentially harmful increase in HDL cho-
lesterol. The change in lipid profile observed from baseline
after 12 months of treatment with torcetrapib was a 72%
increase in HDL cholesterol, a 25% reduction in LDL
cholesterol, and a 9% reduction in fasting triglycerides (5).
Corresponding changes in lipid profile for dalcetrapib were
HDL cholesterol 31% increase, LDL cholesterol 2% de-
crease, triglycerides 3% decrease, and for anacetrapib and
evacetrapib (as monotherapy), respectively, 138% and 132%
increase in HDL cholesterol, 40% and 40% decrease in
LDL cholesterol, and 7% and 20% decrease in triglycerides
(13–15). Thus, although the improvement in antiathero-
genic lipid profiles associated with pharmacological CETP
inhibition were similar, the effect sizes on HDL cholesterol
were, respectively, one-half–fold for dalcetrapib and 10-fold
larger for both anacetrapib and evacetrapib versus torce-
trapib. Nevertheless, only torcetrapib had adverse effects on
cardiovascular endpoints, again suggesting that these were
Figure 3 Risk of Ischemic Heart Disease (IHD), Ischemic Cereb
Stroke as a Function of Cholesteryl Ester Transfer Pro
Participants with IHD and/or ICVD before entry were excluded. Hazard ratios were
tus, smoking, lipid-lowering therapy, alcohol consumption, physical inactivity, and,
are tests for trend of hazard ratios with genotypes coded 0, 1, and 2, or 0, 1, 2, 3due to off-target effects. aRecently, Roche terminated the development of dalce-
trapib after interim analysis of the phase III dal-
OUTCOMES trial (9) showed a lack of clinically mean-
ingful efficacy on cardiovascular events (40). The main
differences between dalcetrapib and the newer CETP in-
hibitors is the more modest increase in HDL cholesterol,
and—probably more important—the almost complete lack
of effect on reducing LDL cholesterol and triglyceride-rich
lipoproteins. Therefore, there is still hope that the newer
CETP inhibitors may improve outcome.
Anacetrapib was reported to associate with a 39% reduction
in lipoprotein(a) (13), an important additional lipoprotein
effect that predicts a potential 12% reduction in cardiovascular
risk (28). Although CETP genotypes overall did not associate
ith levels of lipoprotein(a), Taq1B genotype on the629 CC
ild-type background was associated with stepwise reductions
n levels of lipoprotein(a) of up to 39% in AA homozygotes,
uggesting that a reduction in levels of lipoprotein(a) might be
scular Disease (ICVD), Myocardial Infarction, and Ischemic
Genotype and Genotype Combination in the General Population
ctorially adjusted for sex, age, body mass index, hypertension, diabetes melli-
men, post-menopausal status and hormone replacement therapy. The p values
4. CI  confidence interval.rova
tein
multifa
for wo
, andtrue effect of CETP inhibition.
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November 13, 2012:2041–8 CETP and Ischemic Vascular DiseaseConclusions
We show that genetic CETP inhibition associates with
reductions in risk of IHD, MI, ICVD, and IS, with a
corresponding antiatherogenic lipid profile, and with in-
creased longevity without adverse effects. These findings
together with preliminary results for newer CETP inhibi-
tors provide reassurance that pharmacological inhibition of
CETP may reduce risk of ischemic vascular events and total
mortality, when not accompanied by the off-target effects of
torcetrapib.
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